Administration of astragaloside IV to mice promotes the expression of SIRT1 and activates the SIRT1/Mapt pathway, thereby inhibiting aberrant hyperphosphorylation and hyperacetylation of the microtubule-associated protein Tau, reducing cerebral infarction and rescuing neurological deficits [123]. This evidence concerns the gene MAPT and brain infarction.